Dr. Naresh Somani is an experienced and highly respected medical oncologist in Rajasthan. As the head of the medical oncology department at HCG Cancer Centre in Jaipur, he is an expert in treating patients with immunotherapy & targeted therapies, specialising in cancers of the breast & head and neck region, leukaemias and lymphomas. He has been recognised by Rajasthan Medical Council, Innate Group of Company, India Today Group, Young JMA Achievement Award, Young MPS Achievement Award for his extraordinary performance and humanitarian approach. His treatment approach is focused on providing a personalised care and giving the best possible treatment for each patient.

• Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy.
• The South Asian Journal of Cancer Published Volume 6 Issue,1 January- March 2017
• Nimotuzumab with Concurrent Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN).
• Journal of Cancer Therapy, 2015, 6, 356-361 Published Online April 2015.
• Myelodysplastic Syndromes: A Challenging Disease for Patients and Physicians (JAPI/Feb 2012, VOL. 60)
• Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, Placebo-controlled study (Published in The Lancet Journal Oncology 2012; 13: 154–62)
• Sequential therapy (triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients – Single institute experience ( Nov 2011)
• Intravenous Aflibercept in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites: Key Efficacy and Safety Results of Phase II, Randomised, Double-Blind, Placebo-Controlled Study, ESGO2009, V3 (24 June-09).
• Modified BEACOPP regime as a cost-effective therapy for unfavourable Hodgkin’s disease in underprivileged countries” (Shantanu Sharma, Naresh Somani, S.C. Pande, Nidhi Patni).
• Presented at 38th Annual Conference of the International Society of Paediatric Oncology (SIOP), Geneva, Switzerland, Sept. 2006 and published in “Pediatric Blood & Cancer” Volume 47, Issue 4, Oct. 1, 2006, PJ.017, ISSN 1545-5009.
• A pilot study of BEACOPP (Basic & “modified escalated”) chemotherapy with or without involved-field radiotherapy in Hodgkin’s disease: A cost-effective & risk-stratified protocol in Indian context” (Published in Indian Journal of Medical & Paediatric Oncology – ISSN 0971-5851).
• Activity of specific inhibitor of epidermal growth factor receptor (Gefitinib) in refractory Non-Small-Cell Cancer (NSCLC) – Published in Current Medical Trends – ISSN 0972-3390.
• Review article: systemic treatment of primary breast cancer JAPI, Vol. No. 49, April 2001 (ISSN-0004-5772).Review article: an overview of the management of primary pulmonary lymphoma, Current Medical Trends (ISSN 0972-3390).